RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+18.38%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$8.67B
AUM Growth
+$1.11B
(+15%)
Cap. Flow
+$213M
Cap. Flow
% of AUM
2.46%
Top 10 Holdings %
Top 10 Hldgs %
55.18%
Holding
87
New
9
Increased
9
Reduced
14
Closed
6
Top Buys
| 1 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$177M |
| 2 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$152M |
| 3 |
Vaxcyte
PCVX
|
$55.5M |
| 4 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$46M |
| 5 |
IDEAYA Biosciences
IDYA
|
$42.7M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$88.9M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$75.5M |
| 3 |
Geron
GERN
|
$63.2M |
| 4 |
Ascendis Pharma
ASND
|
$59.4M |
| 5 |
UroGen Pharma
URGN
|
$51.7M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LENZ
26
LENZ Therapeutics
LENZ
$1.14B
| $99.2M | 1.14% |
4,178,823
| – | – |
|
27
PepGen
PEPG
$42M
| $91.4M | 1.05% |
10,689,545
| – | – |
|
28
Axsome Therapeutics
AXSM
$6.21B
| $89.9M | 1.04% |
1,000,000
| – | – |
|
29
Structure Therapeutics
GPCR
$1.14B
| $83.2M | 0.96% |
1,896,772
| – | – |
|
30
Tourmaline Bio
TRML
$645M
| $65.3M | 0.75% |
2,538,925
| – | – |
|
31
Dianthus Therapeutics
DNTH
$794M
| $63.9M | 0.74% |
2,333,000
| – | – |
|
32
Mineralys Therapeutics
MLYS
$2.2B
| $58.7M | 0.68% |
4,850,984
| – | – |
|
33
Acrivon Therapeutics
ACRV
$40.9M
| $58.4M | 0.67% |
8,340,508
| – | – |
|
34
Astria Therapeutics
ATXS
$395M
| $56.2M | 0.65% |
5,105,213
+61,457
| +1% | +$677K |
|
35
4D Molecular Therapeutics
FDMT
$309M
| $55.1M | 0.64% |
5,098,211
| – | – |
|
36
CG Oncology
CGON
$2.36B
| $52.7M | 0.61% |
1,397,433
| – | – |
|
|
BCYC
37
Bicycle Therapeutics
BCYC
$483M
| $51M | 0.59% |
2,253,000
| – | – |
|
38
Nkarta
NKTX
$151M
| $48.8M | 0.56% |
10,805,129
| – | – |
|
|
BIOA
39
BioAge Labs, Inc. Common Stock
BIOA
$169M
| $46M | 0.53% |
+2,210,589
| New | +$46M |
|
40
GH Research
GHRS
$872M
| $44.7M | 0.52% |
6,686,689
+85,000
| +1% | +$569K |
|
41
Praxis Precision Medicines
PRAX
$970M
| $43.8M | 0.51% |
761,955
-473,644
| -38% | -$27.3M |
|
|
42
IDEAYA Biosciences
IDYA
$2.26B
| $42.7M | 0.49% |
+1,347,252
| New | +$42.7M |
|
43
Larimar Therapeutics
LRMR
$331M
| $39.6M | 0.46% |
6,045,351
| – | – |
|
|
MBX
44
MBX Biosciences, Inc. Common Stock
MBX
$434M
| $39.3M | 0.45% |
+1,511,334
| New | +$39.3M |
|
45
Acumen Pharmaceuticals
ABOS
$84.2M
| $37M | 0.43% |
14,932,063
| – | – |
|
46
Fulcrum Therapeutics
FULC
$372M
| $36.5M | 0.42% |
10,229,099
-1,380,605
| -12% | -$4.93M |
|
|
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
| $32.5M | 0.37% |
3,184,711
-332,548
| -9% | -$3.4M |
|
48
Solid Biosciences
SLDB
$433M
| $30.2M | 0.35% |
4,330,446
| – | – |
|
49
C4 Therapeutics
CCCC
$190M
| $27.8M | 0.32% |
4,878,000
| – | – |
|
50
Enliven Therapeutics
ELVN
$1.19B
| $27.1M | 0.31% |
1,061,233
-1,061,232
| -50% | -$27.1M |
|